Anti-Inflammatory Biologics Market Report 2026

The anti-inflammatory biologics market size has grown strongly in recent years. It will grow from $118.02 billion in 2025 to $128.84 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to limited availability of biologics, reliance on traditional anti-inflammatory drugs, increasing prevalence of rheumatoid arthritis and psoriasis, growth of hospital and clinic infrastructure, rising investment in immunology research.

The anti-inflammatory biologics market size is expected to see strong growth in the next few years. It will grow to $180.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to development of next-generation cytokine inhibitors, expansion of home care and self-administration options, increasing regulatory approvals and faster clinical trial processes, rising investment in precision medicine and biologics R&D, growing partnerships between pharma and biotech companies. Major trends in the forecast period include rising adoption of targeted biologics for chronic inflammatory diseases, expansion of subcutaneous and injectable drug delivery, growing clinical trials and research for novel anti-inflammatory biologics, increased focus on personalized treatment plans, rising awareness and access to biologics in emerging markets.

The increasing prevalence of arthritis is anticipated to drive the growth of the anti-inflammatory biologics market in the coming years. Arthritis is a condition characterized by inflammation or swelling in one or more joints, leading to pain, stiffness, and limited mobility, which often worsens with age. The growing incidence of arthritis is largely attributed to rising obesity levels, as excess body weight puts additional strain on joints, contributing to inflammation and joint deterioration. Anti-inflammatory biologics play a key role in arthritis management by targeting specific elements of the immune system to reduce inflammation, slow the progression of joint damage, alleviate symptoms, and enhance physical function and overall quality of life for individuals with moderate to severe arthritis. For instance, in January 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in 2023, 18.4% of individuals aged 16 years and older reported having a long-term musculoskeletal (MSK) condition, an increase from 17.6% in 2022. Therefore, the rising prevalence of arthritis is contributing to the growth of the anti-inflammatory biologics market.

Major companies operating in the anti-inflammatory biologics market are concentrating on the development of innovative therapies, such as interleukin-6 (IL-6) receptor antagonists, to treat chronic inflammatory diseases with improved precision and fewer side effects. Interleukin-6 (IL-6) receptor antagonists are biologic medications that inhibit the IL-6 receptor, thereby reducing inflammatory and immune responses in conditions including rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for Kevzara as the first and only biologic therapy indicated for patients with polymyalgia rheumatica (PMR) who have an inadequate response to corticosteroids. Kevzara is a fully human monoclonal antibody that blocks the IL-6 receptor, helping to reduce inflammation associated with PMR, a disorder characterized by muscle pain and stiffness, particularly among older adults. Compared to long-term steroid use, which is associated with risks such as osteoporosis and diabetes, Kevzara offers a targeted, steroid-sparing treatment option that supports better patient outcomes and improved long-term safety.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen aims to reinforce its position in innovative therapies for serious diseases by expanding its portfolio in rare and autoimmune conditions, accelerating growth, and increasing global patient access to first-in-class treatments. Horizon Therapeutics plc is an Ireland-based company engaged in the development of multiple anti-inflammatory biologic therapies.

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A.

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-inflammatory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the anti-inflammatory biologics market by increasing costs for imported raw materials, active pharmaceutical ingredients, and specialized manufacturing equipment. Segments such as tumor necrosis factor inhibitors and interleukin inhibitors are particularly impacted, with Asia-Pacific regions including China and India facing the highest import duties. This has led to higher production costs and supply chain adjustments. However, tariffs have also incentivized domestic manufacturing, innovation in biologics production, and strategic partnerships, which can strengthen local capabilities and market resilience.

The anti-inflammatory biologics market research report is one of a series of new reports that provides anti-inflammatory biologics market statistics, including anti-inflammatory biologics industry global market size, regional shares, competitors with a anti-inflammatory biologics market share, detailed anti-inflammatory biologics market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory biologics industry. This anti-inflammatory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-inflammatory biologics are therapeutic agents produced from living organisms that selectively target specific elements of the immune system to suppress inflammation. They are widely used in the treatment of chronic inflammatory disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease by inhibiting cytokines or immune cells that drive inflammatory responses.

The main drug classes of anti-inflammatory biologics include tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors, T-cell inhibitors, and others. Tumor necrosis factor inhibitors are biologic therapies that block the action of tumor necrosis factor-alpha, a key mediator of inflammation in the body, thereby helping to alleviate symptoms of autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. These drugs are administered through various routes, including oral, injectable, intravenous, and subcutaneous methods. They are used across multiple applications, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other indications, and are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. These therapies are utilized by a broad range of end users, including hospitals, clinics, home care settings, and research and academic institutions.

The anti-inflammatory biologics market consists of sales of adalimumab, etanercept, infliximab, ustekinumab, and secukinumab. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.